ADPT Adaptive Biotechnologies Corp
Q3 2025 10-Q
Filed: Nov 5, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Adaptive Biotechnologies Corp (ADPT) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • Newly added risk: Termination of Genentech Agreement in Aug 2025, with wind-down completing Feb 2026 may materially impact business and financial condition
- • Most materially updated risk: Loss of exclusive oncology collaboration may reduce Immune Medicine revenue to sequencing service fees only, lowering comparability to prior periods
Quarterly Financial SummaryXBRL
Revenue
$94M
▲ +102.4% YoY▲ +59.6% QoQ
Net Income
$10M
▲ +129.8% YoY▲ +137.3% QoQ
Operating Margin
10.9%
▲ +8122bp YoY▲ +5347bp QoQ
Net Margin
10.2%
▲ +7922bp YoY▲ +5366bp QoQ
ROE
4.7%
Total Assets
$491M
EPS (Diluted)
$0.07
▲ +131.8% YoY▲ +141.2% QoQ
Operating Cash Flow
-$7M
▲ +73.7% YoY▲ +42.7% QoQ
Source: XBRL data from Adaptive Biotechnologies Corp Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Adaptive Biotechnologies Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.